{
    "body": "What is  the clinical value of naltrexone in Parkinson's disease patients?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/152622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11254789", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7969211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23634190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25037206"
    ], 
    "ideal_answer": [
        "Naltrexone does not improve clinical features, including motor function, in Parkinson's disease patients. Naltrexone was shown to be effective for treatment of pathological gambling in Parkinson's disease patients."
    ], 
    "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:14330", 
        "http://www.biosemantics.org/jochem#4249647"
    ], 
    "type": "summary", 
    "id": "55033064e9bde69634000036", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 93, 
            "text": "Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 535, 
            "offsetInEndSection": 685, 
            "text": "These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 843, 
            "offsetInEndSection": 948, 
            "text": "CONCLUSIONS: The opioid antagonist naltrexone could be an effective option for the treatment of PG in PD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 282, 
            "offsetInEndSection": 350, 
            "text": "No improvement in the clinical features of either disorder was noted", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/152622", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 102, 
            "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 415, 
            "offsetInEndSection": 529, 
            "text": "Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 101, 
            "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinsons disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", 
            "endSection": "title"
        }
    ]
}